Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.
about
Early implementation of QbD in biopharmaceutical development: a practical exampleHuman Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.Design of a platform technology for systemic delivery of siRNA to tumours using rolling circle transcription.Type W Human Endogenous Retrovirus (HERV-W) Integrations and Their Mobilization by L1 Machinery: Contribution to the Human Transcriptome and Impact on the Host Physiopathology.Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study.[Endogenous retroviral sequences in the human genome can play a physiological or pathological role].Treatment against human endogenous retrovirus: a possible personalized medicine approach for multiple sclerosis.The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis.Trials of antivirals in the treatment of multiple sclerosis.HERV Envelope Proteins: Physiological Role and Pathogenic Potential in Cancer and Autoimmunity.[Implication of human endogenous retroviruses in schizophrenia and bipolar disorder].Human Endogenous Retroviruses Are Ancient Acquired Elements Still Shaping Innate Immune Responses
P2860
Q26830466-A9310746-F9FA-4403-9440-1E189D80EF2CQ36869897-C45063E7-209D-42FA-9727-80C8126B5427Q37019872-5AC9DA36-CCEE-4BC2-BA6E-F81B2461BD5CQ37031856-FAFBE618-34CC-4BBD-B5FE-55829869C215Q38707294-D3A8B228-2412-4A9D-BBED-409A701FDCF7Q39013294-6D713F1D-B0F6-486D-9692-D3AABAE833C5Q39876276-2D73C16E-85FE-4C4C-81E0-BC269D645442Q40204275-A8D4CC96-4EAD-4731-851F-ED67FA1C9D81Q41351593-5903D9DE-7FA7-40D3-A05E-622229C5B58DQ47226723-C6272695-FABC-49D6-A545-45B7CF9CD175Q47600963-D4648C82-3344-436B-8AB0-919665CFA88FQ52338720-1B3E4D58-96D5-4942-9DE7-C227595CA12FQ53297737-5095BCB5-50B1-4601-AA9B-6BF6EA32F762Q58754303-0FF9581D-B56E-4C2A-B388-732784EAB569
P2860
Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Preclinical and early clinical ...... s retroviral MSRV-Env protein.
@ast
Preclinical and early clinical ...... s retroviral MSRV-Env protein.
@en
type
label
Preclinical and early clinical ...... s retroviral MSRV-Env protein.
@ast
Preclinical and early clinical ...... s retroviral MSRV-Env protein.
@en
prefLabel
Preclinical and early clinical ...... s retroviral MSRV-Env protein.
@ast
Preclinical and early clinical ...... s retroviral MSRV-Env protein.
@en
P2093
P2860
P1476
Preclinical and early clinical ...... s retroviral MSRV-Env protein.
@en
P2093
Alois B Lang
Arno Kromminga
François Curtin
Hervé Perron
Hervé Porchet
P2860
P304
P356
10.4161/19420862.2014.985021
P577
2015-01-01T00:00:00Z